Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nexxen International (NEXN) Cash & Equivalents (2020 - 2025)

Nexxen International (NEXN) has disclosed Cash & Equivalents for 6 consecutive years, with $133.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 28.74% to $133.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $133.3 million through Dec 2025, down 28.74% year-over-year, with the annual reading at $133.3 million for FY2025, 28.74% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $133.3 million at Nexxen International, down from $187.1 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $367.7 million in Q4 2021, with the low at $133.3 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $228.0 million, with a median of $217.5 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 277.29% in 2021, then plummeted 40.85% in 2022.
  • Over 5 years, Cash & Equivalents stood at $367.7 million in 2021, then tumbled by 40.85% to $217.5 million in 2022, then rose by 7.73% to $234.3 million in 2023, then dropped by 20.16% to $187.1 million in 2024, then decreased by 28.74% to $133.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $133.3 million, $187.1 million, and $234.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.